Study of immunogenicity and safety of a candidate rotavirus vaccine based on a recombinant hybrid protein

Abstract

BACKGROUND: Rotaviruses are the main cause of acute gastroenteritis in children in both developed and developing countries. Vaccination is the only way to prevent severe and fatal course of this disease. Live attenuated viruses-based vaccines currently available can have a number of side effects. A candidate rotavirus vaccine reported is based on a hybrid recombinant protein FliCVP6VP8, which includes a VP6 protein fragment, a rotavirus A VP8 protein fragment, and S. typhimurium FliC flagellin components.

AIM: The aim was to evaluate the immunogenicity and safety of а preparation “Rotavirus vaccine, recombinant” in preclinical studies.

MATERIALS AND METHODS: The immunogenicity of vaccine (blood antibody titers, antigen-specific proliferative response of spleen cells) was evaluated in BALB/c mice. The acute and subchronic toxicity, the possible irritating effect, pyrogenicity and the anaphylactic effect and delayed type hypersensitivity were evaluated in laboratory mice, rats, Guinea pigs, and rabbits.

RESULTS: Double immunization of mice with the candidate vaccine demonstrated a significant increase in antibody titers in mouse sera compared to that in control mice. Evaluation of antigen-specific proliferative response after double immunization with a candidate vaccine demonstrated a significant increase in the values of stimulated proliferation. Evaluation of safety through acute and chronic toxicity studies demonstrated no toxicity. The immunostimulatory effect of vaccine was demonstrated when evaluating the number of antibody-producing cells with sheep red blood cells as antigens. The number of white blood cells was demonstrated to increase after the prolonged vaccine administration.

CONCLUSIONS: The preclinical studies have demonstrated safety of the candidate rotavirus vaccine and its capability to produce the immune response.

Keywords

rotavirus, vaccine / immunogenicity / toxicity / anaphylaxis / immunotoxicity / preclinical studies

References

[1] Dukhovlinov IV, Bogomolova EG, Fedorova EA, Simbirtsev AS. Development of hybrid recombinant proteins based on VP6 proteins and VP8 rotavirus human group A. Infection and Immunity. 2014;4(3):229–234. (In Russ.). DOI: 10.15789/2220-7619-2014-3-229-234

[2] Духовлинов И.В., Богомолова Е.Г., Федорова Е.А., Симбирцев А.С. Создание гибридных рекомбинантных белков на основе белков VP6 и VP8 ротавируса человека группы А // Инфекция и иммунитет. 2014. Т. 4, № 3. C. 229–234. DOI: 10.15789/2220-7619-2014-3-229-234

[3] Dukhovlinov IV, Bogomolova EG, Fedorova EA, Simbirtsev AS. Study of the protective activity of the candidate vaccine against rotavirus infection based on the recombinant protein FliCVP6VP8. Medical immunology. 2016;18(5):417–424. (In Russ.). DOI: 10.15789/1563-0625-2016-5-417-424

[4] Духовлинов И.В., Богомолова Е.Г., Федорова Е.А., Симбирцев А.С. Исследование протективной активности кандидатной вакцины против ротавирусной инфекции на основе рекомбинантного белка FliCVP6VP8 // Медицинская иммунология. 2016. Т. 18, № 5. С. 417–424. DOI: 10.15789/1563-0625-2016-5-417-424

[5] Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv. Ed. by A.N. Mironov. Part one. Moscow; 2013. (In Russ.)

[6] Руководство по проведению доклинических исследований лекарственных средств / под ред. А.Н. Миронова. Часть первая. Москва, 2013.

[7] Gosudarstvennaya farmakopeya Rossijskoj Federacii XIII izdaniye: v 3 t. Moscow; 2015. (In Russ.)

[8] Государственная фармакопея Российской Федерации, XIII издание: в 3 т. М., 2015.

[9] GOST 58173-2018. Sredstva lekarstvennye dlya medicinskogo primeneniya. Immunotoxicity investigations intended for humans pharmaceuticals. Moscow: Standartinform; 2018. (In Russ.)

[10] ГОСТ 58173-2018. Средства лекарственные для медицинского применения. Исследования иммунотоксичности лекарственных средств, предназначенных для человека. Москва: Стандартинформ, 2018.

[11] Dukhovlinov IV, Bogomolova EG, Fedorova EA, Simbirtsev AS. Study of the immunogenicity of hybrid recombinant proteins based on VP6 and VP8 proteins of rotavirus human group A. Epidemiology and Vaccinal Prevention. 2015;14(2(81)):96–101. (In Russ.). DOI: 10.31631/2073-3046-2015-14-2-96-101

[12] Духовлинов И.В., Богомолова Е.Г., Федорова Е.А., Симбирцев А.С. Изучение иммуногенности гибридных рекомбинантных белков на основе белков VP6 и VP8 ротавируса человека группы А // Эпидемиология и вакцинопрофилактика. 2015. Т. 14, № 2(81). С. 96–101. DOI: 10.31631/2073-3046-2015-14-2-96-101

[13] GOST R 56699–2015. Medicines for medical applications. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. General recommendations. Moscow: Standartinform; 2016. (In Russ.)

[14] ГОСТ Р 56699–2015. Лекарственные средства для медицинского применения. Доклинические исследования безопасности биотехнологических лекарственных препаратов. Общие рекомендации. Москва: Стандартинформ, 2016.

[15] Bhandari N, Rongsen-Chandola T, Bavdekar A, et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9935):2136–2143. DOI: 10.1016/S0140-6736(13)62630-6

[16] Bhandari N., Rongsen-Chandola T., Bavdekar A. et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial // Lancet. 2014. Vol. 383, No. 9935. P. 2136–2143. DOI: 10.1016/S0140-6736(13)62630-6

[17] Jerne NK, Nordin AA. Plaque formation in agar by single antibody-producing cells. Science. 1963;140(3365):405. DOI: 10.1126/science.140.3565.405

[18] Jerne N.K., Nordin A.A. Plaque formation in agar by single antibody-producing cells // Science. 1963. Vol. 140, No. 3365. P. 405. DOI: 10.1126/science.140.3565.405

[19] Elliott EJ. Acute gastroenteritis in children. BMJ. 2007;334(7583):35–40. DOI: 10.1136/bmj.39036.406169.80

[20] Elliott E.J. Acute gastroenteritis in children // BMJ. 2007. Vol. 334, No. 7583. P. 35–40. DOI: 10.1136/bmj.39036.406169.80

[21] Hajam IA, Dar PA, Shahnawaz I, et al. Bacterial flagellin – a potent immunomodulatory agent. Exp Mol Med. 2017;49(9):e373. DOI: 10.1038/emm.2017.172

[22] Hajam I.A., Dar P.A., Shahnawaz I. et al. Bacterial flagellin – a potent immunomodulatory agent // Exp. Mol. Med. 2017. Vol. 49, No. 9. P. e373. DOI: 10.1038/emm.2017.172

[23] Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood. 2003;102(7):2660–2669. DOI: 10.1182/blood-2003-04-1078

[24] Hayashi F., Means T.K., Luster A.D. Toll-like receptors stimulate human neutrophil function // Blood. 2003. Vol. 102, No. 7. P. 2660–2669. DOI: 10.1182/blood-2003-04-1078

[25] Munos MK, Walker CLF, Black RE. The effect of rotavirus vaccine on diarrhea mortality. Int J Epidemiol. 2010;39(Suppl 1):i56–i62. DOI: 10.1093/ije/dyq022

[26] Munos M.K., Walker C.L.F., Black R.E. The effect of rotavirus vaccine on diarrhea mortality // Int. J. Epidemiol. 2010. Vol. 39, No. Suppl 1. P. i56–i62. DOI: 10.1093/ije/dyq022

[27] Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children. MMWR Recomm Rep. 2006;55(RR–12):1–13.

[28] Parashar U.D., Alexander J.P., Glass R.I. Prevention of rotavirus gastroenteritis among infants and children // MMWR Recomm. Rep. 2006. Vol. 55, No. RR–12. P. 1–13.

[29] Revelas A. Acute gastroenteritis among children in the developing world. South Afr J Epidemiol Infect. 2012;27(4):156–162. DOI: 10.1080/10158782.2012.11441503

[30] Revelas A. Acute gastroenteritis among children in the developing world // South Afr. J. Epidemiol. Infect. 2012. Vol. 27, No. 4. P. 156–162. DOI: 10.1080/10158782.2012.11441503

[31] Tsybalova LM, Stepanova LA, Potapchuk MV, et al. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2E peptide into the immunodominant region of hepatitis B cort antigen: broad protective efficacy of particles carrying four copies of M2E. Vaccine. 2015;33(29):3398–3406. DOI: 10.1016/j.vaccine.2015.04.073

[32] Tsybalova L.M., Stepanova L.A., Potapchuk M.V. et al. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2E peptide into the immunodominant region of hepatitis B cort antigen: broad protective efficacy of particles carrying four copies of M2E // Vaccine. 2015. Vol. 33, No. 29. P. 3398–3406. DOI: 10.1016/j.vaccine.2015.04.073

[33] Weigle WO, Cochrane CG, Dixon FJ. Anaphylactogenic properties of soluble antigen-antibody complexes in the guinea pig and rabbit. J Immunol. 1960;85:469–477.

[34] Weigle W.O., Cochrane C.G., Dixon F.J. Anaphylactogenic properties of soluble antigen-antibody complexes in the guinea pig and rabbit // J. Immunol. 1960. Vol. 85. P. 469–477.

[35] Wyant TL, Tanner MK, Sztein MB. Salmonella typhi flagella are potent inducers of proinflammatory cytokine secretion by human monocytes. Infect Immun. 1999;67(7):3619–3624. DOI: 10.1128/IAI.67.7.3619-3624.1999

[36] Wyant T.L., Tanner M.K., Sztein M.B. Salmonella typhi flagella are potent inducers of proinflammatory cytokine secretion by human monocytes // Infect. Immun. 1999. Vol. 67, No. 7. P. 3619–3624. DOI: 10.1128/IAI.67.7.3619-3624.1999

[37] Lappalainen S, Pastor AR, Tamminen K, et al. Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo. Hum Vaccin Immunother. 2014;10(7):2039–2047. DOI: 10.4161/hv.28858

[38] Lappalainen S., Pastor A.R., Tamminen K. et al. Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo // Hum. Vaccin Immunother. 2014. Vol. 10, No. 7. P. 2039–2047. DOI: 10.4161/hv.28858

RIGHTS & PERMISSIONS

Varyushina E.A., Alexandrov G.V., Zakharov M.S., Kiryanova A.S., Huttunen O.E., Rumyantseva A.B., Mitrofanov I.D., Bendt I.V., Krylova A.E., Chistyakova A.B., Artemova N.A., Shatillo I.M., Bogomolova E.G., Dobrovolskaya O.A., Ischuk S.A., Dukhovlinov I.V., Simbirtsev A.S.